Senti Biosciences (NASDAQ:SNTI) Shares Climb 15.2% – Should You Buy?

Senti Biosciences, Inc. (NASDAQ:SNTI) was up 15.2% on Wednesday. The company traded as high as $0.2307 and last traded at $0.2151. 9,836,723 shares changed hands during mid-day trading, an increase of 700% from the average session volume of 1,229,019 shares. The stock had previously closed at $0.1867.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Senti Biosciences has an average rating of “Moderate Buy” and an average target price of $9.00.

Senti Biosciences Price Performance

The business’s fifty day simple moving average is $0.30 and its 200-day simple moving average is $0.73.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.08). The firm had revenue of $0.02 million for the quarter. On average, equities analysts expect that Senti Biosciences, Inc. will post -1.53 earnings per share for the current year.

Senti Biosciences Company Profile

Senti Biosciences, Inc is a biotechnology company developing gene and cell therapies for cancer and other serious diseases. The company’s technology is based on synthetic biology, including programmable gene circuits designed to help engineered immune cells recognize disease-associated targets, respond to specific biological signals and limit activity in healthy tissue.

Senti Biosciences applies its platform to the development of engineered cell therapies, including chimeric antigen receptor natural killer (CAR-NK) and other immune-cell programs.